MX380989B - Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo. - Google Patents
Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo.Info
- Publication number
- MX380989B MX380989B MX2018009741A MX2018009741A MX380989B MX 380989 B MX380989 B MX 380989B MX 2018009741 A MX2018009741 A MX 2018009741A MX 2018009741 A MX2018009741 A MX 2018009741A MX 380989 B MX380989 B MX 380989B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- pharmaceutically acceptable
- acceptable salt
- composition containing
- kinase inhibitor
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 150000003839 salts Chemical class 0.000 title abstract 3
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- ODYDEDBPRBMSKE-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrole-2-carboxamide Chemical compound C1CCC2CN(C(=O)N)CC21 ODYDEDBPRBMSKE-UHFFFAOYSA-N 0.000 abstract 1
- 229920003086 cellulose ether Polymers 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente invención se proporciona una composición farmacéutica que contiene un inhibidor de la Janus quinasa ( JAK) o una sal farmacéuticamente aceptable del mismo. En particular, en la presente invención se proporciona una composición farmacéutica que contiene (3aR,5s, 6aS)- N-(3- metoxi- 1, 2, 4- tiadiazol- 5- il)-5-( metil(7H-pirrolo[ 2, 3- d] pirimidina-4- il)amino)hexahidrociclopenta[ c] pirrol-2( 1 H)- carboxamida, o una sal farmacéuticamente aceptable de la misma, y éter de celulosa. La composición farmacéutica de la presente invención se caracteriza por una tasa de disolución rápida y buena estabilidad.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610094168 | 2016-02-19 | ||
| PCT/CN2017/073869 WO2017140254A1 (zh) | 2016-02-19 | 2017-02-17 | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018009741A MX2018009741A (es) | 2018-11-09 |
| MX380989B true MX380989B (es) | 2025-03-12 |
Family
ID=59624719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018009741A MX380989B (es) | 2016-02-19 | 2017-02-17 | Composición farmacéutica que contiene un inhibidor de janus quinasa o una sal farmacéuticamente aceptable del mismo. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10786507B2 (es) |
| EP (1) | EP3417861B1 (es) |
| JP (1) | JP6875407B2 (es) |
| KR (1) | KR20180109992A (es) |
| CN (1) | CN107530348B (es) |
| AU (1) | AU2017220971A1 (es) |
| BR (1) | BR112018015369A2 (es) |
| CA (1) | CA3014090A1 (es) |
| MX (1) | MX380989B (es) |
| RU (1) | RU2744432C2 (es) |
| TW (1) | TWI745349B (es) |
| WO (1) | WO2017140254A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293319B1 (en) | 2016-08-16 | 2026-01-01 | Beone Medicines Ltd | Crystal structure of s)–7–(1–acryloylpiperidin–4–yl)–2–(4–)phenoxyphenyl)–4,5,6,7–tetra–hydropyrazolo(1,5–a)pyrimidine–3–carboxamide, methods of preparation and uses thereof |
| TW201827436A (zh) * | 2017-01-20 | 2018-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種jak激酶抑制劑的硫酸氫鹽的晶型及其製備方法 |
| CN111205290B (zh) * | 2018-11-22 | 2021-10-08 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的结晶形式及其制备方法 |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP3981399A4 (en) | 2019-06-10 | 2023-05-31 | BeiGene Switzerland GmbH | ORAL SOLID TABLET WITH A TYROSINE KINAS INHIBITOR AND METHOD OF MANUFACTURE THEREOF |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| CN114727965B (zh) * | 2019-12-23 | 2023-12-12 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂药物组合物 |
| BR112022010101A2 (pt) * | 2019-12-31 | 2022-09-06 | Pfizer R&D Uk Ltd | Formulações em comprimido e cápsula de liberação imediata estáveis de 1-((2s,5r)-5-((7h-pirrol[2,3-d]pirimidin-4-il)amino)-2-metilpiperidin-1-il)prop-2-en-1-ona |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| BR112023001283A2 (pt) | 2020-07-28 | 2023-02-14 | Arcutis Biotherapeutics Inc | Composição farmacêutica tópica; método para tratar uma doença, distúrbio ou afecção inflamatória de pele em um indivíduo que necessita do mesmo; e método para intensificar a penetração em pele em um indivíduo de uma formulação farmacêutica tópica |
| US20230414511A1 (en) | 2020-11-17 | 2023-12-28 | Arcutis Biotherapeutics, Inc. | Compositions and methods for deep dermal drug delivery |
| TW202227452A (zh) * | 2020-12-04 | 2022-07-16 | 大陸商廣州費米子科技有限責任公司 | 氮雜並環化合物、其製備方法、抑制酪氨酸激酶的方法、藥物組成物及其用途 |
| CN113813228B (zh) * | 2021-10-11 | 2023-04-18 | 北京鑫开元医药科技有限公司 | 一种具有jak激酶抑制活性的注射液及其制备方法和用途 |
| CN118632687A (zh) | 2021-11-11 | 2024-09-10 | 阿尔库缇斯生物疗法股份有限公司 | 用于深层皮肤药物递送的螺内酯药物组合物 |
| EP4447930A1 (en) | 2021-12-15 | 2024-10-23 | Arcutis Biotherapeutics, Inc. | Stable formulations of shr0302 |
| CN120641104A (zh) * | 2023-02-07 | 2025-09-12 | 瑞石生物医药有限公司 | 一种局部给药的药物组合物、其制备方法及应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| JP6075736B2 (ja) * | 2011-12-21 | 2017-02-08 | ジエンス ヘンルイ メデイシンカンパニー リミテッドJiangsu Hengrui Medicine Co.,Ltd. | ピロール−6員ヘテロアリール環誘導体、その合成法およびその医薬用途 |
| CN104470927B (zh) * | 2013-06-07 | 2016-05-04 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐及其制备方法 |
| CN105566327A (zh) | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| SI3216790T1 (sl) | 2014-11-05 | 2020-02-28 | Jiangsu Hengrui Medicine Co., Ltd., | Kristalinična oblika bisulfata inhibitorja JAK-kinaze in postopek priprave le-te |
-
2017
- 2017-02-17 BR BR112018015369-9A patent/BR112018015369A2/pt not_active IP Right Cessation
- 2017-02-17 CA CA3014090A patent/CA3014090A1/en not_active Abandoned
- 2017-02-17 US US16/077,135 patent/US10786507B2/en not_active Expired - Fee Related
- 2017-02-17 KR KR1020187025163A patent/KR20180109992A/ko not_active Withdrawn
- 2017-02-17 WO PCT/CN2017/073869 patent/WO2017140254A1/zh not_active Ceased
- 2017-02-17 JP JP2018537438A patent/JP6875407B2/ja not_active Expired - Fee Related
- 2017-02-17 CN CN201780001376.6A patent/CN107530348B/zh active Active
- 2017-02-17 RU RU2018129775A patent/RU2744432C2/ru active
- 2017-02-17 EP EP17752686.0A patent/EP3417861B1/en not_active Not-in-force
- 2017-02-17 AU AU2017220971A patent/AU2017220971A1/en not_active Abandoned
- 2017-02-17 MX MX2018009741A patent/MX380989B/es unknown
- 2017-02-18 TW TW106105457A patent/TWI745349B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3417861B1 (en) | 2020-09-23 |
| KR20180109992A (ko) | 2018-10-08 |
| WO2017140254A1 (zh) | 2017-08-24 |
| CN107530348B (zh) | 2020-10-20 |
| TW201729812A (zh) | 2017-09-01 |
| CA3014090A1 (en) | 2017-08-24 |
| RU2744432C2 (ru) | 2021-03-09 |
| TWI745349B (zh) | 2021-11-11 |
| US20190030033A1 (en) | 2019-01-31 |
| AU2017220971A1 (en) | 2018-08-02 |
| JP2019505525A (ja) | 2019-02-28 |
| RU2018129775A (ru) | 2020-03-19 |
| EP3417861A4 (en) | 2019-09-18 |
| MX2018009741A (es) | 2018-11-09 |
| EP3417861A1 (en) | 2018-12-26 |
| US10786507B2 (en) | 2020-09-29 |
| BR112018015369A2 (pt) | 2018-12-18 |
| RU2018129775A3 (es) | 2020-05-25 |
| HK1244704A1 (zh) | 2018-08-17 |
| CN107530348A (zh) | 2018-01-02 |
| JP6875407B2 (ja) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018009741A (es) | Composicion farmaceutica que contiene un inhibidor de janus quinasa o una sal farmaceuticamente aceptable del mismo. | |
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| ZA202103587B (en) | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors | |
| WO2020115555A3 (en) | Crf1 receptor antagonist, pharmaceutical formulations and solid forms thereof for the treatment of congenital adrenal hyperplasia | |
| MD4735B1 (ro) | Derivaţi ai pirolo[2,3-d]pirimidinei ca inhibitori de Kinaze Janus-asociate (JAK) | |
| MX380928B (es) | Inhibidores de kras g12c. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| PH12016501310B1 (en) | Pharmaceutical compositions comprising azd9291 | |
| MX2015016513A (es) | Bisulfato del inhibidor de la janus quinasa (jak) y metodo de preparacion para el mismo. | |
| PH12021550687A1 (en) | Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt | |
| PH12017500724A1 (en) | Carbazole derivatives | |
| WO2016109217A3 (en) | Btk inhibitors | |
| PE20170773A1 (es) | Formulaciones farmaceuticas, procesos para la preparacion, y metodos de uso | |
| EP4275707A3 (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| MX2022001743A (es) | Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. | |
| CO2021010493A2 (es) | Compuestos de halo-alilamina y uso de los mismos | |
| AU2020278236A8 (en) | Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor | |
| MX2020008929A (es) | Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico. | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| MX384146B (es) | Triple combinación de antagonistas del receptor de 5-ht6 puro, inhibidores de acetilcolinesterasa y antagonista del receptor de nmda. | |
| MX2021014830A (es) | Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi. | |
| CO2018002046A2 (es) | Nueva composición oral de libreación retardada dual de dexlansoprazol | |
| HK1252549A1 (zh) | 控释tozadenant制剂 | |
| MX381175B (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. |